FDA approves inhalable diabetes drug Afrezza

The U.S. Department of Health and Human Services building which houses the Food and Drug Administration (FDA) in Rockville, MD. (File) (Getty Images)
The U.S. Department of Health and Human Services building which houses the Food and Drug Administration (FDA) in Rockville, MD. (File) (Getty Images)
Set Text Size SmallSet Text Size MediumSet Text Size LargeSet Text Size X-Large
Share
Updated: 6/27 3:42 pm

WASHINGTON (AP) — The Food and Drug Administration on Friday said that it has approved a long-delayed inhalable diabetes medication, designed to help patients control their blood sugar levels.

The FDA cleared MannKind Corp.'s drug Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans. The approval decision comes more than three years after the agency first asked MannKind to run additional clinical studies on the drug.

Afrezza, an insulin powder, comes in a single-use cartridge and is designed to be inhaled at the start of a meal. MannKind has said patients using the drug can achieve peak insulin levels within 12 to 15 minutes. 

That compares to a wait time of an hour and a half or more after patients inject insulin.

©2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Share
NEWSCASTS ON DEMAND

What's On

All content © Copyright 2014 Intermountain West Communications Company. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.
You may also view our Sitemap

Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.